Selenite-induced p53 ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells

Molecular Cancer Therapeutics

Volumn 3, Issue 7, 2004, Pages 877-884

  Jiang, Cheng ^a   Hu, Hongbo ^a   Malewicz, Barbara ^a   Wang, Zaisen ^a,b   Lü, Junxuan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; CASPASE 8; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PIFITHRINE ALPHA; PROTEIN INHIBITOR; PROTEIN P53; SERINE; SINGLE STRANDED DNA; SODIUM SELENITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; BENZOTHIAZOLES; CASPASES; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MALE; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; SERINE; SODIUM SELENITE; THIAZOLES; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4444295544     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
2. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81:730-4.
3. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers & Prev 2002;11:630-9.
4. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. Br J Urol Int 2003;91:608-12.
5. Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res 1997;56: 117-24.
6. Lu J, Kaeck M, Jiang C, Wilson AC, Thompson HJ. Selenite induction of DNA strand breaks and apoptosis in mouse leukemic L1210 cells. Biochem Pharmacol 1994;47:1531-5.
7. Lu J, Jiang C, Kaeck M, et al. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995;50:213-9.
8. Kaeck M, Lu J, Strange R, Ip C, Ganther HE, Thompson HJ. Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol 1997;53:921-6.
9. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001;61:3062-70.
10. Jiang C, Wang Z, Ganther H, Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002;1:1059-66.
11. Kim T, Jung U, Cho DY, Chung AS. Se-methylselenocysteine induces apoptosis through caspase activation in HL-60 cells. Carcinogenesis 2001;22:559-65.
12. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993;23: 123-34.
13. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 1985;82:790-4.
14. Lane DP, Lu X, Hupp T, Hall PA. The role of the p53 protein in the apoptotic response. Philos Trans R Soc Lond B Biol Sci 1994;345:277-80.
15. Morgan SE, Kasten MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 1997;71:1-25.
16. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644-55.
17. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res 2001;82:55-84.
18. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-57.
19. Meek DW. Mechanisms of switching on p53: a role for covalent modification? Oncogene 1999;18:7666-75.
20. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325-34.
21. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997;11:3471-81.
22. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal - regulated protein kinases and p38 kinase. Cancer Res 2001;61:1604-10.
23. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 2001;61:8723-9.
24. Mroz RM, Holownia A, Chyczewska E, Chyczewski L, Braszko JJ. p53 N-terminal Ser-15-P and Ser-20-P levels in squamous cell lung cancer after radio/chemotherapy. Am J Respir Cell Mol Biol 2004;30: 564-8.
25. Lanfear J, Fleming J, Wu L, Webster G, Harrison PR. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium? Carcinogenesis 1994;15: 1387-92.
26. Jiang C, Jiang W, Ip C, Ganther H, Lu J. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 1999;26:213-25.
27. Margolin N, Raybuck SA, Wilson KP, et al. Substrate and inhibitor specificity of interleukin-1 β-converting enzyme and related caspases. J Biol Chem 1997;272:7223-8.
28. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-7.
29. Menter DG, Sabichi AL, Lippman, SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers & Prev 2000; 9:1171-82.
30. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 2001;61:7071-8.
31. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-90.
32. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 1999;274:20049-52.
33. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum - specific apoptosis and cytotoxicity by amyloid-β. Nature 2000;403:98-103.
34. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281: 1677-9.
35. Kim ST, Lim DS, Canman CE, Kastan MB. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 1999;274:37538-43.
36. Zhou N, Xiao H, Li TK, Nur EKA, Liu LF. DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem 2003;278: 29532-7.
37. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces, apoptosis. J Cell Biol 1994;124:619-26.
38. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
39. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
40. Ip C, Birringer M, Block E, et al. Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J Agric Food Chem 2000;48:2062-70.
41. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis 2000;3:145-51.